Literature DB >> 27133825

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).

M Mossner1, J-C Jann1, D Nowak1, U Platzbecker2, A Giagounidis3, K Götze4, A Letsch5, D Haase6, K Shirneshan6, F Braulke6, R F Schlenk7, T Haferlach8, P Schafhausen9, G Bug10, M Lübbert11, A Ganser12, G Büsche13, E Schuler14, V Nowak1, J Pressler1, J Obländer1, S Fey1, N Müller1, E Lauinger-Lörsch1, G Metzgeroth1, C Weiß15, W-K Hofmann1, U Germing14, F Nolte1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27133825     DOI： 10.1038/leu.2016.111

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors:  Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

Authors:  E Schuler; A Giagounidis; D Haase; K Shirneshan; G Büsche; U Platzbecker; F Nolte; K Götze; R F Schlenk; A Ganser; A Letsch; F Braulke; M Lübbert; G Bug; P Schafhausen; U Bacher; N Gattermann; M Wulfert; R Haas; U Germing
Journal:  Leukemia       Date:  2015-12-15       Impact factor: 11.528

3.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Authors:  D A Sallman; R Komrokji; C Vaupel; T Cluzeau; S M Geyer; K L McGraw; N H Al Ali; J Lancet; M J McGinniss; S Nahas; A E Smith; A Kulasekararaj; G Mufti; A List; J Hall; E Padron
Journal:  Leukemia       Date:  2015-10-30       Impact factor: 11.528

4.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

Authors:  Austin G Kulasekararaj; Alexander E Smith; Syed A Mian; Azim M Mohamedali; Pramila Krishnamurthy; Nicholas C Lea; Joop Gäken; Coralie Pennaneach; Robin Ireland; Barbara Czepulkowski; Sabine Pomplun; Judith C Marsh; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2013-01-09       Impact factor: 6.998

6.  Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Authors:  Ramin Tehranchi; Petter S Woll; Kristina Anderson; Natalija Buza-Vidas; Takuo Mizukami; Adam J Mead; Ingbritt Astrand-Grundström; Bodil Strömbeck; Andrea Horvat; Helen Ferry; Rakesh Singh Dhanda; Robert Hast; Tobias Rydén; Paresh Vyas; Gudrun Göhring; Brigitte Schlegelberger; Bertil Johansson; Eva Hellström-Lindberg; Alan List; Lars Nilsson; Sten Eirik W Jacobsen
Journal:  N Engl J Med       Date:  2010-09-09       Impact factor: 91.245

7.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome.

Authors:  Y Kita-Sasai; S Horiike; S Misawa; H Kaneko; M Kobayashi; M Nakao; H Nakagawa; H Fujii; M Taniwaki
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

8.  NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

Authors:  Carrie Fidler; Fiona Watkins; David T Bowen; Timothy J Littlewood; James S Wainscoat; Jacqueline Boultwood
Journal:  Haematologica       Date:  2004-07       Impact factor: 9.941

9.  Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Authors:  Martin Jädersten; Leonie Saft; Andrea Pellagatti; Gudrun Göhring; James S Wainscoat; Jacqueline Boultwood; Anna Porwit; Brigitte Schlegelberger; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

10.  Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

Authors:  A Kuendgen; M Lauseker; A F List; P Fenaux; A A Giagounidis; N A Brandenburg; J Backstrom; A Glasmacher; J Hasford; U Germing
Journal:  Leukemia       Date:  2012-12-21       Impact factor: 11.528
View more
  17 in total

Review 1.  Implications of molecular genetic diversity in myelodysplastic syndromes.

Authors:  Rafael Bejar
Journal:  Curr Opin Hematol       Date:  2017-03       Impact factor: 3.284

2.  Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations.

Authors:  Laurence Lodé; Adam Ameur; Thibault Coste; Audrey Ménard; Steven Richebourg; Jean-Baptiste Gaillard; Yannick Le Bris; Marie-Christine Béné; Thierry Lavabre-Bertrand; Thierry Soussi
Journal:  Haematologica       Date:  2017-10-27       Impact factor: 9.941

3.  Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?

Authors:  Guillermo F Sanz; Mariam Ibañez; Esperanza Such
Journal:  Blood Adv       Date:  2019-11-12

Review 4.  Current treatment algorithm for the management of lower-risk MDS.

Authors:  Aristoteles Giagounidis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.

Authors:  James A Kennedy; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

Review 6.  Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

Authors:  Alex Aleshin; Peter L Greenberg
Journal:  Blood Adv       Date:  2018-10-23

7.  Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: a case report.

Authors:  Yujie Chen; Rafee Talukder; Brian Y Merritt; Katherine Y King; Marek Kimmel; Gustavo Rivero; Romina Sosa
Journal:  BMC Med Genomics       Date:  2021-05-22       Impact factor: 3.063

8.  Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

Authors:  Anna Hecht; Julia A Meyer; Johann-Christoph Jann; Katja Sockel; Aristoteles Giagounidis; Katharina S Götze; Anne Letsch; Detlef Haase; Richard F Schlenk; Torsten Haferlach; Philippe Schafhausen; Gesine Bug; Michael Lübbert; Felicitas Thol; Guntram Büsche; Esther Schuler; Verena Nowak; Julia Obländer; Stephanie Fey; Nadine Müller; Georgia Metzgeroth; Wolf-Karsten Hofmann; Ulrich Germing; Florian Nolte; Mark Reinwald; Daniel Nowak
Journal:  Ann Hematol       Date:  2021-04-27       Impact factor: 3.673

9.  Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.

Authors:  Satoko Oka; Kazuo Ono; Masaharu Nohgawa
Journal:  Ann Hematol       Date:  2017-06-02       Impact factor: 3.673

Review 10.  Myelodysplastic syndromes: moving towards personalized management.

Authors:  Eva Hellström-Lindberg; Magnus Tobiasson; Peter Greenberg
Journal:  Haematologica       Date:  2020-05-21       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.